## Molecular Genetics of Osteosarcoma **Key Point:** Osteosarcoma is a genetically heterogeneous tumor with multiple pathways to malignant transformation. Understanding the frequency and significance of key mutations is essential for prognosis and emerging targeted therapy strategies. ### Genetic Alterations in Osteosarcoma | Genetic Event | Frequency | Significance | |---|---|---| | **TP53 mutations** | >50% sporadic cases | Loss of p53 checkpoint control; associated with Li–Fraumeni syndrome | | **RB1 loss** | ~20–30% | Hereditary retinoblastoma patients have 500–fold increased risk of secondary osteosarcoma | | **KRAS mutations** | ~10–20% | Present in minority of cases; NOT the most frequent alteration | | **c-MYC amplification** | ~10–15% | Associated with aggressive behavior and poor prognosis | | **CDKN2A/p16 loss** | ~10–20% | Cell cycle dysregulation | | **Complex karyotype** | Most cases | Aneuploidy and multiple chromosomal rearrangements typical | ### Why Option 3 is Incorrect **High-Yield:** KRAS mutations are found in only **10–20%** of osteosarcomas, NOT >80%. This is a common misconception. While KRAS is important in some cases, osteosarcoma is characterized by **genetic heterogeneity** — no single mutation dominates. TP53 loss is the most frequent single genetic event. **Clinical Pearl:** The genetic complexity of osteosarcoma explains why single-agent targeted therapy (e.g., KRAS inhibitors alone) has limited efficacy. Current research focuses on combination strategies targeting multiple pathways. ### Correct Statements (Options 1, 2, 4) **Option 1 — TP53 mutations (>50%):** Correct. This is the most common genetic alteration and is the hallmark of Li–Fraumeni syndrome, which confers a lifetime osteosarcoma risk of ~10%. **Option 2 — RB1 and hereditary retinoblastoma:** Correct. Patients with germline RB1 mutations have a 500–1000-fold increased risk of secondary osteosarcoma, especially after radiation therapy (as in this case). **Option 4 — c-MYC amplification:** Correct. Amplification of c-MYC is associated with increased proliferation and aggressive osteosarcoma phenotype, though it occurs in a subset of cases. **Mnemonic: TP53-RB-MYC** — The **T**hree major pathways in osteosarcoma: **TP53** loss (most common), **RB** loss (hereditary risk), **MYC** amplification (aggressive phenotype).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.